Related Breaking News

IGI Laboratories, Inc. has entered into a three-year agreement with Juventio, LLC to manufacture and supply finished dose forms of certain cosmetic and OTC products and formulations owned and developed by IGI. The products use IGI’s encapsulation technology Novasome. Juventio, based in NJ, distributes non-prescription health products, in partnership with healthcare professionals.

Jason Grenfell-Gardner, president and chief executive officer of IGI, said, “We are excited to partner with Juventio, and utilize our existing Novasome technology to provide turnkey manufacturing services. The utilization of our own technology and know-how enables us to achieve higher margins on these products, which brings us one step closer to achieving our goal of profitability in 2013. The agreement, which includes a total of $3.0 million of minimum purchases over the contract lifespan, is a testament to our focus to expand our higher-margin, committed contract services business.”

Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important